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Abstract.  Glycoprotein llb-IRa (ctnbB3) and the 
vitronectin receptor (ct~B3), two integrins  that share the 
common #3 subunit, have been reported to function as 
promiscuous receptors for the RGD-containing adhe- 
sive proteins fibrinogen, vitronectin,  fibronectin,  yon 
Willebrand factor, and thrombospondin.  The present 
study was designed to establish a cell system for the 
expression of either GP IIb-IIIa or the vitronectin 
receptor in an otherwise identical cellular environment 
and to compare the adhesive properties of these two 
integrins  with those of native GP IIb-iRa and the 
vitronectin receptor constitutively expressed in HEL 
cells or platelets.  M21 human melanoma cells lack GP 
Hb-IIIa and use the vitronectin receptor to attach to 
vitronectin,  fibrinogen, fibronectin, and yon Wille- 
brand factor. To study the functional properties of GP 
IIb-IIIa in these cells, we transfected GP lab into 
M21-L cells, a variant of M21 cells (Cheresh,  D. A., 
and R. C.  Spiro.  1987. J.  Biol. Chem. 262:17703- 
17711),  which lack the expression of functional ctv and 
are therefore unable to attach to vitronectin,  fibrino- 
gen,  and yon Willebrand factor.  Transfectants express- 
ing GP IIb were isolated by immunomagnetic beads 
and surface expression of the GP lib-IRa complex was 
documented by FACS analysis and immunoprecipita- 
tion experiments performed with 125I-labeled M21-L/ 
GP n'b cells.  Comparative functional studies demon- 
strated that GP llb-IIIa expressed in M21-L/GPIlb 
cells as well as native GP Ilb-tlla constitutively ex- 
pressed in HEL-5J20 cells (an HEL variant lacking ctv~3) 
mediated cell attachment to immobilized fibrinogen, but 
not to vitronectin or von WiUebrand factor, whereas 
the vitronectin receptor expressed in M21 cells and 
HEL-AD1 cells (an HEL variant expressing c~v/33) me- 
diated cell attachment to fibrinogen, vitronectin,  and 
von Willebrand factor.  Similarly,  PGl2-treated resting 
platelets attached to immobilized fibrinogen but not to 
vitronectin or von Willebrand factor, and this attach- 
ment could be inhibited by mAb A2A9 (directed against 
a  functional site on the GP IIb-iRa complex). How- 
ever, in contrast to platelets,  which adhered to vitro- 
nectin and von Willebrand factor after stimulation by 
thrombin or PMA, activation of the protein kinase C 
pathway in M21-L/GP Ilb or HEL cells did not induce 
cell adhesion to vitronectin or von Willebrand factor. 
Our results therefore demonstrate (a) that while GP 
IIb-I]Ia in its inactive,  resting form is capable of me- 
diating adhesion of platelets to immobilized fibrino- 
gen, it does not to other RGD-containing adhesive 
proteins such as von Willebrand factor and vitronec- 
tin,  and (b) that GP Ilb-iRa expressed in nucleated 
cells has similar adhesive properties as does GP llb- 
IRa in resting platelets but is not activated by platelet 
stimuli. 
I 
NTEGRINS are a widely distributed  family of cell surface 
proteins that evolved from a common ancestor to per- 
form a variety of cellular adhesion  functions  (Hynes, 
1987). During hemostasis and thrombosis, integrins  of the 
platelet membrane play an essential role in mediating adhe- 
sion of platelets  to extracelhlar matrix proteins exposed at 
the site of injury of the vessel wall,  as well as fibrinogen- 
dependent aggregation of platelets with each other (reviewed 
in Phillips  et al.,  1988).  Two /33 integrins  of the platelet 
membrane, GPIIb-IlIa (ctnb/~3) and the vitronectin  receptor 
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(ctv/33), share  the same/3 subunit  and have ct subunits  that 
are 36% homologous (Fitzgerald et al., 1987). Both GP ITo- 
llIa and the vitronectin  receptor (VnR) have been shown to 
function as promiscuous receptors for the adhesive proteins 
fibrinogen,  vitronectin,  von Willebrand  factor, fibronectin, 
and  thrombospondin  involved  in  platelet-subendothelium 
and platelet-platelet interactions.  The multiple ligand-bind- 
ing capability of these receptors is due to their ability to bind 
to the Arg-Gly-Asp (RGD) recognition  sequence (Ruoslahti 
and Pierschbacher,  1987). Fibrinogen contains two RGD se- 
quences in its Act chain,  at residues 95-97 and 572-574 
(Doolittle  et al.,  1979).  A  second site  on fibrinogen  that 
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the carboxy-terminus of the -/chain of fibrinogen (Klocze- 
wiak et al., 1984). This dodecapeptide sequence is not found 
in other adhesive proteins, but competes with RGD-contain- 
ing peptides for binding to GP I/b-Ilia (l_atm et al.,  1987). 
Equilibrium binding studies have shown that GP Ilb-IIIa 
contains a single RGD binding site (Steiner et al., 1989). On 
GP lab-Ilia and the VnR, this RGD binding site appears simi- 
lar as photoaflinity cross-linking studies with ~25I-RGD con- 
taining peptides have identified the same domain on the 13 
subunit for both receptors (D'Souza et al., 1988; Smith and 
Cheresh,  1988).  Despite the structural similarities and the 
apparent identity of the RGD-binding sites of GPilb-HIa and 
the VnR, differences in ligand-receptor interactions individ- 
ualize the two receptors. In nucleated cells, the VnR function 
is constitutive, allowing it to function essentially as a cell 
adhesion receptor, whereas the receptor function of GPI/b- 
Ilia in platelets is manifest only after cell activation. VnR- 
mediated attachment of endothelial cells to immobilized fi- 
brinogen uses exclusively the RGD binding site, whereas 
GPl/b-ilIa mediated attachment of activated platelets to fi- 
brinogen occurs not only via the RGD sites but also the 
dodecapeptide (Cheresh et al., 1989) which has been found 
to cross-link primarily to GPIIb (D'Souza et al.,  1990). 
Receptor-ligand interaction studies for GP lib-Ilia and the 
VnR  have  been  performed essentially by  comparing  the 
adhesive properties of different cell types expressing a given 
receptor or by using purified receptor assays.  However,  a 
major drawback of whole cell assays is the presence of  multi- 
ple integrin receptors on a given cell (e.g., platelets express 
at least six integrins:  GP Ilb-IIla,  the VnR (Lam et al., 
1989),  ~2~ (Kunicki et al.,  1988),  ~5/3~ (Piotrowicz et al., 
1988), a6/3~ (Hemler et al., 1988).  Purified receptor assays 
also have limitations as they do not take into account the 
microenvironment of the receptor in the plasma membrane, 
such as receptor-phospholipid interactions, receptor-cyto- 
skeleton interactions, or conformational changes of the mol- 
ecule that might be important for receptor activation and 
function, and indeed, functional differences depending on 
the microenvironment have been  noted for the VnR  otv/33 
(Conforti et al., 1990) and for oe2Bt (Kirchhofer et al., 1989; 
Elites and Hemler,  1989). 
To gain some further insight in the functional properties 
of GP Ilb-IIIa and the VnR, a  clear advantage for recep- 
tor-ligand binding studies would be the existence of stable 
cell models that express either GP I/b-Ilia or the VnR in an 
otherwise identical cellular environment. With the availabil- 
ity of complete cDNA sequences encoding integrin recep- 
tors, the design of such experimental cell models has now 
become possible and transient expression of recombinant 
platelet GP Iib-illa has been achieved in COS cells (O~l'oole 
et al., 1989) and human embryonic kidney ceils (Bodary et 
al.,  1989).  However,  these cell lines constitutively express 
a VnR that competes with recombinant GP lib-Ilia in adhe- 
sion assays designed to study functional properties of GP 
Iib-ilIa.  Also,  extensive structural  studies of the  recom- 
binant receptor are limited by the small number of cells ex- 
pressing the transfected receptor as well as their short life 
span. Here we describe the establishment of stable cell sys- 
tems expressing either GP II'b-ilIa or the VnR in the same 
cellular environment. By studying the functional properties 
of recombinant GP IIb-illa expressed in M21-L cells and ha- 
rive GP IIb-ilIa constitutively expressed in HEL cells and 
platelets, we demonstrate a new functional role of the inac- 
tive, resting form of GP l/b-Ilia in mediating cell attachment 
to immobilized fibrinogen, but not to other RGD-containing 
adhesive proteins  such  as  vitronectin or  yon Willebrand 
factor. 
Materials and Methods 
Cells and Cell Culture 
Platelets were isolated from healthy adult donors by differential centrifnga- 
t.ion of whole blood anticongulated  with 1/6 vol of acid/citrate/dextrose  (71 
mM citric acid,  85 mM sodium citrate, 110 mM glucose) and 1 #M PGI2 
as previously described (Cheresh et al., 1989). The human melanoma cells 
M21 (called here M21-W for wild type) and M21-L are those described by 
Cheresh and Spiro (1987). Two subelones of the initial HEL cell line (Mar- 
tin and Papayannopoulou,  1982) were used: the clone HEL-5J20 has a high 
surface  expression  of GP llb-l]Ja and only background expression of the 
VnR, whereas the clone HEL-AD1 expresses equal amounts ofGP Ilb-HIa 
and the VnR. The cells were grown in RPMI medium (Gibco Laboratories, 
Grand Island, NY) supplemented with 10%  FCS (Gibco Laboratories), 
100 U/ml of penicillin, and 100 ttg/ml of streptomycin  in 5% CO2 in a 
fully humidified incubator at 37°C. COS-'/cells (SV40 transformed African 
green monkey  kidney)  (Gluzman,  1981) were  grown in DME  medium 
(Gibeo Laboratories) supplemented  with 10% FCS and antibiotics as de- 
scribed above. 
mAbs 
The following mAbs were used in this study. S1 was produced in our labora- 
tory and reacts with GP IIba in Western blot; SZ21 (Amac Corp., Westbrook, 
ME) is directed against GP IIIa; A2A9 is a complex-specific  GP Ilb-nIa 
antibody (Bennett et al., 1983), LM609 a complex-specific VnR antibody 
(Cheresh and Spiro, 1987), and BIIG2 a complex-dependent  llbronectin re- 
ceptor antibody (Werb et al.,  1989). All mouse mAbs were isolated from 
ascites fluid and purified on a protein-A Scpharose immunoabsorbent  (Phar- 
macia Fine Chemicals, Piscataway, NJ). The rat BIIG2 mAbs were purified 
from aseites fluid by ammonium sulfate precipitation followed by chroma- 
tography on a DEAE column. 
Plasmid Construct 
For plasmid construction, we used the expression vector pBJ1, which was 
kindly provided by Dr. Mark Davis (Stanford  University School of Medi- 
cine). The pBJ1 vector is a modified form of the PeD-SRc~ expression clon- 
ing vector described by Takebe et al. (1988) that contains the simian virus 
40 (SV40) early promoter and the R segment and part of the RU sequence 
(R-U5') of the long terminal repeat of the human T cell leukemia virus type 
1 (HTLV-1). A human eDNA for GP lib was isolated from a commercially 
prepared HEL cell eDNA library (Stratagene Corp., La Jolla, CA) using 
an oligonucleotide  probe,  which represented the first 42 nucleotides  of the 
published sequence (Poncz et al., 1987). An EcoRI-Hindlll  fragment  was 
subcloned into M13  mpl8  (Boehringer Mannheim Biochemicals,  Indi- 
anapolis, IN), and the Y-end of the clone was completed using site-directed 
mutagenesis (Kunkel,  1985). This involved adding 2 nucleotides,  such that 
the GP lib eDNA contained nucleofides  1-3203 of the published sequence. 
The full-length GP lib coding sequence was inserted into the EcoRI site of 
the pBJ1 vector. The resulting  plasmid, designated pBJI-GP Ilb, was charac- 
terized by restriction mapping and transient expression  in COS cells. 
Transfection of  M21-L Cells 
M21-L cells were transfected using the lipofection method (Feigner et al., 
1987). 48 h before transfection,  106 cells were plated on fibronectin-coated 
100 nun dishes.  At day 0, the cells were washed twice with serum-free 
RPMI medium and then incubated for 24 h with 20 ~tg of pB.I1-GP Iro plas- 
mid DNA and 4/zg of pSVneo plasmid DNA, mixed in a 1:1 volume with 
lipofectin 0Bethesda Research Laboratories, Gaithersburg,  MD) according 
to the manufacturer's procedure. The next day, complete medium was added 
and the cells allowed to grow for 4 more days. The cells were then detached 
with EDTA buffer, pH 7.4 (1 mM EDTA,  [50 mM NaCi, 50 mM Hepes) 
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surface expression of GP  Ilb-IIIa using mAb S1  and immunomngnetic 
beads coated with polyclonal rabbit anti-mouse IgG (Dynal Inc., Great 
Neck, NY). Briefly, the cells (106 cells/100 ~d) were incubated for 30 rain 
at4*C with 10/~g of SI-IgG, washed with RPMI and incubated for a further 
30 min under gentle agitation at 4"C with 3  ×  l0  s immunomngnetic beads 
in a final volume of 2 ml. Magnetic bead cell rosettes were separated from 
negative cells using a  magnetic particle concentrator (Dynal Inc.). The 
selected cells were then plated on fibrinogen-coated dishes. After 24 h, 
nonadherent cells were washed off. Adherent cells were grown to a higher 
cell density in the presence of 1 mg/mi of G418-sulfate (Gibco Laborato- 
ries)  and  reselected twice  for  GPfib-lIIa  expression by  fluorescence- 
activated cell sorting. 
COS Cell Transfection 
COS-7 cells were transfected using the lipofection method. Briefly,  5  × 
10  s  cells were plated onto 90-ram culture dishes.  When the cells had 
reached 70 % confluency, transfectiun was performed with 10/~g of pBII-GP 
fib plasmid DNA as described above. The cells were then metabolically la- 
beled for 24--48 h after transfection and processed for irnmunoprecipitation 
experiments as described in the following section. 
Immunofluorescence Analysis of  Receptor Expression 
GP Igo-HIa and VnR expression was analyzed on M21-L-transfected cells 
in  suspension using  indirect  immunofluorescence and  a  fluorescence- 
activated cell sorter (FACS 440;  Becton-Dickinson Co., Mountain View, 
CA). Adherent cells were detached by incubating the cells for 5 min at 37°C 
with EDTA buffer. The cells were then immediately washed and resus- 
pended in RPMI medium. These experimental conditions have previously 
been shown to induce only minimal irreversible GP ITo-Ilh complex dis- 
sociation in human platelets (Fitzgerald and Phillips, 1985).  The cells were 
f~rtber incubated at 40C for 30 rain at 106 cells/100/~1  in RPMI medium 
containing 10/~g of monoclonal mouse IgG. The cells were then washed 
with RPMI  and  incubated with  FITC-cunjngated goat anti-mouse IgG 
(Cappel Laboratories, West Chester, PA) for 30 rain at 4"C. Positive flu- 
orescence  was determined on a four-decade log scale and expressed as chan- 
nel number of mean intensity of fluorescence (MIF).I Background fluores- 
cence was determined for each cell population using FITC-conjugated goat 
anti-mouse IgG alone.  The cytometric data were obtained with the as- 
sistance of the UCSF Laboratory for Cell Analysis. 
Cell Radiolabeling and Immunoprecipitation 
For  12sI surface  labeling,  the  evils  were  detached  with  EDTA  buffer, 
washed twice with PBS and resnspended at 107 cells/mi in PBS. Labeling 
was performed by the laetoperoxidase catalyzed iodination procedure as 
previously described (Kieffer  et al., 1986). For steady state metabolic label- 
ing, adherent cells were washed twice with RPMI medium and then cultured 
for 30 rain at 37"C in methionine and cysteine free RPMI medium sup- 
plemented with heat inactivated, dialyzed FCS.  After 30 rain,  250 t~Ci 
[3SS]methionine  and 250 t~Ci [3SS]eysteine (specific activity >800 Ci/mM; 
Amersham Corp., Arlington Heights, IL) were added to the medium and 
the cells cultured for 24 h at 37"C. The cells were then washed twice with 
RPMI, detached with EDTA buffer, and resuspended at 5  ×  107 cells/ml 
in PBS. For immunoprecipitation, radiolabeled cells were lyzed in lysis 
buffer, pH 7.4 (10 mM Tris, 150 mM NaCI,  1% Triton X-100, 0.1% SDS, 
2 raM PMSF). Triton X-100 insoluble material was removed by ultracen- 
trifngation, and lysate samples, corresponding to 5  ×  106 cells were incu- 
bated with 5/~g ofmAb IgO. After 3 h at 4"C, 25 t~l of  protein A-Sepharose 
CL-4B (Pharmacia Fine Chemicals) were added and the incubation con- 
tinued for 30 rain at 4"C. Protein A-Sepharose  beads were washed six times 
with lysis buffer, and the final pellet resuspended in 50/~1 of 10 mM Tris- 
HCl, pH Z4,  containing 2%  (wt/vol) SDS and 5%  2-mercaptoethanol. 
Bound proteins were eluted by boiling the suspension for 5 nfin and ana- 
lyzed by SDS-PAGE according to the method of Laernmli (1970).  After 
electrophoresis, the gels were fixed and when required processed for fluo- 
rography with Amplify (Amersham Corp.). The gels were then dried and 
exposed at  -800C to FUJI RX films. 
1. Abbreviations used in this paper: GP, glycoprotein; MIF, mean fluores- 
cence intensity; VnR, vitronectin receptor. 
Cell Adhesion Assay 
M21-L/GP IIb cells and M21-L cells were metabolically labeled overnight 
with [35S]methionine  as described above and were then washed twice with 
RPMI medium. The cells were detached with EDTA buffer, washed and 
resuspended in RPMI medium at I06 cel]s/ml. Before the adhesion assay, 
the cells were incubated with I0/~g of the appropriate mAb or inhibitor for 
30 rain at 4°C. The cells (5  x  104) were then added to individual wefts of 
microtiter plates previously coated with the adhesive protein (10/~g/rnl  in 
RPMI medium). Cell attachment was allowed to occur at 37°C for 3 h, after 
which microtiter wells were washed with RPMI medium to remove unat- 
tached cells. The remaining cells were lyzed with 2 % SDS and radioactivity 
counted in a/~ scintillation counter (LS1701; Beckman Instruments, Palo 
Alto, CA). For platelet adhesion studies, platelets were isolated from blood 
collected in  acid-citrate-dextrose anticoagulant  containing  1  I~M  PGI2 
(Sigma Chemical Co., St. Louis, MO). After centrifugation of the blood 
at 160 g for 15 rain, the platelet rich plasma was removed and subjected 
to gel filtration over a Sepharose 2B column. Platelets were then pelleted 
and resuspended at 2  ×  l0  s cells per ml in 0.002 M Hepes, pH 7.35, con- 
raining 0.15 M NaC1, 0.005 M dextrose and 1 mg/ml BSA. Platelets were 
activated with either 0.5 NIH unlts/ml of thrombin or 50/~M PMA for 10 
rain at 220C or treated with 1 #M PG12, and the adhesion assay performed 
as described by Cheresh et al.  (1989).  The adhesive proteins flbrinogen, 
vitronectin, and fibronectin were purified from human plasma according to 
published procedures (Kazal et al.,  1963; Engvall et ai., 1978; Yatohga et 
al., 1988),  and were essentially devoid of contaminating proteins as deter- 
mined by SDS-PAGE and Coomussie blue staining of the gel. BSA (fraction 
V) was purchased from Sigma Chemical Co. 
Results 
Transfection of GPIIb cDNA into M21-L Cells 
As previously reported by Cheresh and Spiro (1987), M21-L 
cells are a variant cell clone of  the human melanoma cell line 
M21 and lack the VnR o~ chain or its mRNA but do produce 
normal levels of the/33 chain that accumulates within the 
cell. A full-length eDNA clone containing the entire coding 
sequence of GP lib  was  constructed as described in the 
Materials and Methods section, subcloned into the expres- 
sion vector pBJl, and introduced into the M21-L adherent 
cells using lipofectin. To select for transfected M21-L cells 
expressing a fully complexed GP Ilb-HIa receptor, positive 
transfectants were immunoselected using GP llb mAb S1 and 
immunomagnetic beads coated with rabbit anti-mouse IgG. 
A typical result is illustrated in Fig.  1, which shows a few 
rosette-forming cells and a nonnegligible number of  negative 
cells, most likely entrapped in the pellet of free magnetic 
beads (Fig. 1 A). Selected transfectants were thereafter plated 
on fibrinogen-coated microtiter wells. The rosette forming 
cells were found to attach and spread, whereas the negative 
cells did not and thus could be partially washed off (Fig. 1 
B).  The  selected cells were then grown to a  higher cell 
density, reselected twice by cell sorting using mAb S1 and 
finally subcloned by limiting dilution. 
Surface Expression of the GP lib-Ilia Complex in 
M21-L Cells Transfected with GP lib 
To study the surface expression of the GP llb-IIIa complex 
in transfected M21-L/GP Hb cells, indirect immunofluores- 
cence was performed on cells in suspension using monoclo- 
nal antibodies specific for either the GP lib  subunit (S1) 
or  the  GP  Hb-l~a  complex  (A2A9)  and  analyzed on  a 
fluorescence-activated cell sorter. The results shown in Table 
I are expressed as numeric data ofMIE Nonspecific fluores- 
cence was determined for each cell type by incubating the 
cells with FITC-conjugated goat anti-mouse IgG alone (MIF 
Kieffer et al. Properties of GP llb-llla Expressed in Human Melanoma Cells  453 Figure 1.  Phase-contrast micrographs of M21-L/GP IIb transfected cells after immunoselection using the GP lib mAb S1 and goat 
anti-mouse-coated magnetic beads. (A) Phase view of selected cells. The arrow points to a rosette forming cell. (B) Selected cells after 
24 h spreading on a fibrinogen-coated  microtiter plate. The arrow points to an attached rosette. Bar, 22.5/~m. MB, magnetic bead; NC, 
negative cell; R, rosette-forming cell. 
<  40).  The transfected M21-L/GP lib cells were positive 
with both mAb S1  (MIF 70)  and mAb A2A9  (MIF 81), 
whereas they were negative with the VnR mAb LM609 (MIF 
35).  Nontransfected M21-L control cells were negative for 
all three mAbs (MIF 28), whereas M21-wild-type cells ex- 
hibited positive fluorescence with mAb LM609 (MIF 77) 
and were negative with mAb S1  (MIF 32). 
Biosynthesis and Posttranslational Processing 
of  GP lib in M21-L/GP lib Cells as Compared with 
COS/GP lib Cells 
As a prelude to functional analysis of the transfected protein, 
experiments  were performed to  determine whether post- 
translational processing of GP fib had occurred. A simple 
procedure to demonstrate posttranslational processing of a 
glycoprotein is based on the change of its molecular weight, 
visualized by a change in the electrophoretic mobility of the 
glycoprotein when submitted to SDS-PAGE analysis. To de- 
termine whether posttranslational processing of GP fib-IIIa 
occurred in M21-L/GP IIb cells, we compared the apparent 
molecular weight of GP fib or GP I~a immunoprecipitated 
from transfected M21-L/GP fib cells and COS/GP fib cells 
as well as cells that constitutively express GP Ilb-IIIa, such 
as platelets or HEL cells. In an initial experiment shown in 
Fig. 2,  M21-L/GP fib cells and platelets were ~"I-surface 
labeled, lysed and immunoprecipitated with the GP fib-Ilia 
mAb A2A9. Under nonreducing conditions, the precipitated 
GP lib-Ilia from M21-L/GP llb cells had a molecular mass 
of  140,000  and 95,000  respectively and comigrated with 
platelet GP fib and GP ll]a 0anes A-C).  After disulfide 
cleavage,  the electrophoretic mobility of both subunits un- 
derwent the characteristic shift identical to that observed for 
platelet GP fib and GP Ilia, with the appearance of the GP 
fib/3 subunlt (lanes D-F).  A  similar result was obtained 
when GP fib-IRa from M2bL/GP fib was compared with 
HEL cell GP Ilb-ma (data not shown). Thus, GPIlb in M21- 
L/GP Ilb cells had undergone posttranslational cleavage.  In 
contrast, when experiments were performed using metaboli- 
cally labeled COS cells that had been transfected with the 
same pBJ1/GP fib vector, only unprocessed pro-GP fib was 
immunoprecipitated with mAh $1, whereas the same mAh 
precipitated pro-GP fib as well as the processed GP llb-lBa 
complex from metabolically labeled  HEL cells  (Fig.  3). 
These results thus provide evidence that normal posttransla- 
tional proteolytic processing  of GP fib  into  its ot  and 
Table I. lmmunofluorescence Flow Cytometric Analysis 
of  M21 Cell Clones  for Surface Expression of  GP llb-llla 
and the VnR 
M21 cell clone 
Antibody  M21-W  M21-L  M21-L/GP lib 
Negative control 
(second Ab alone)  34  23  30 
Anti-GP llb (¢x  Ilb) 
(Sl)  32  23  70 
Ami-GP I1b-IIIa (¢xmB3) 
(A2A9)  34  27  81 
Anti-VnR (¢x~B3) 
(LM 609)  77  28  35 
Flow cytometry analysis of M21-W-, M21-L-,  and M21-L/GP IIb-~ansfected 
cells for  surface expression of the 83  integrins GP Ilb-IIIa and the VnR. 
Washed, unfixed cells (I06) were stained by indirect immunofluorescence  and 
analyzed by flow cytometry analysis as described in Materials  and Methods. 
Each profile was geaerated from an analysis of I0,000 cells. Relative  values 
of MIF were derived from gated computerized  histogram analysis  and ex- 
pressed as channel number of the histogram axis.  Nonspecific  fluorescence 
measured with the second fluorescein isothiocyanate antibody alone was found 
<channel 40 and considered as negative. 
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of GP Hb-IHa from ~2SI-sur- 
face  labeled  M21-L/GP  IIb 
ceils and platelets.  Detergent 
extracts of ~2SI-surface  labeled 
M21-L/GP Hb cells and plate- 
lets  were incubated  with GP 
Hb-IIIa mAb A2A9 and  the 
immune  complexes  precipi- 
tated  with  protein  A-Sepha- 
rose.  Precipitated  proteins 
were  analyzed  on  a  %12% 
SDS-PAGE  gel under nonre- 
ducing conditions (lanes A-C) 
or reducing conditions  (lanes 
D-F).  Lanes  C  and F,,  total 
profile  of t25I-surface labeled 
platelets;  lanes  B and E, GP 
Ilb-llIa  immunoprecipitated 
from platelets;  lanes A and D, 
GP  IIb-IIIa immunoprecipi- 
tated from transfected  M21-L/ 
GP lib cells. 
subunits  occurred  in  M21-L/GP  lib  cells,  but  did  not  in 
COS/GP lib  cells.  Also,  comigration of GP IIb-llla from 
M21-L/GP llb cells with platelet GP Ub-llla suggests effec- 
tive  posttranslational  glycosylation,  since  Duperray  et  al. 
Figure 3. lmmunoprecipitation of GP llb from transfected  COS/GP 
llb ceils or HEL-5J20 cells.  Detergent extracts of [35S]methionine 
and  [35S]cysteine labeled  COStGP IIb cells  or HEL-5J20 cells 
were incubated with 10/~g of anti-GP IFo IgG (mAb SI). Immune 
complexes were precipitated  with protein-A Sepharose and ana- 
lyzed by SDS-PAGE  under reducing conditions.  Lanes  1 and 4: 
negative control; lanes 2 and 3, immunoprecipitates obtained with 
mAb S1 from transfected  COS/GPIlb cells 0ane 2) or HEL-5J20 
cells (lane 3). 
Figure 4. SDS-PAGE analysis of immunoprocipitates  from M21-W, 
M21-L, and transfeeted  M21-L/GP lib cells.  Detergent extracts  of 
[~SS]methionine and  [35S]cysteine labeled  ceils  were  incubated 
with 10 #g ofmAb-IgG. Immune complexes were precipitated  with 
protein A-Sepharose  and analyzed by SDS-PAGE under reducing 
conditions.  Lane A,, negative control; lane B, GP IRa mAb SZ21; 
lane C, GP l/b-IRa mAb A2A9; lane D, GP IIb mAb S1; lane E, 
VnR mAb LM609. 
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GP  Rb-IRa has  an  increased  electrophoretic  mobility  as 
compared with normal GP l/b-IRa. 
To exclude the possibility that our selection procedure al- 
lowed the isolation of a revertant M21-L cell expressing the 
VnR, and to further document biosynthesis of GP l/b-IRa, 
immunoprecipitation  experiments  were  performed  using 
steady-state metabolically labeled M21-L/GP IIb cells. The 
result is shown in Fig. 4. No VnR could be immunoprecipi- 
tated from M21-L/GP I~ cells, whereas mAb A2A9, S1, and 
SZ21  all precipitated two bands corresponding to GP fib- 
IRa. Immunoprecipitations performed on M21-W and M21-L 
cells confirmed their typical phenotype, i.e., the presence of 
the VnR in M21-W  cells and the free/~3 subunit in M21-L 
cells. 
Functional Properties of GP lib-Ilia in M21-L/GP lib 
Cells, HEL Cells, and Platelets 
(a) GP lib-Ilia Expressed in M21-L Cells Mediates Cell 
Attachment  to Fibrinogen  But Not to  Vitronectin,  von 
Vdllebrand Factor, or Fibronectin.  To study the functional 
properties of GP Hb-IIIa  and the VnR individually expressed 
in M21 melanoma cells, a cell adhesion assay was performed 
on microtiter plates coated with various adhesive proteins 
(Fig. 5). In accordance with previous results (Cheresh and 
O 
Spiro,  1987),  M21  cells  expressing  the  VnR  attached  to  o 
fibrinogen, vitronectin, von Willebrand factor, and fibronec-  × 
tin, whereas mock transfected M21-L ceils, which express 
ob/31, only  attached  to  fibronectin.  When  M21-L/GP  lib 
transfectants were tested, they attached to fibrinogen as well 
as fibronectin, however, they did not attach to vitronectin or  z:E 
von Willebrand factor, nor could adhesion to vitronectin or  ,~ 
von  Willebrand  factor  be  induced  by  PMA.  (result  not  ~'< 
shown). To determine whether the M21-L/GP lib cell inter-  = 
action with fibrinogen or fibronectin was GP l/b-IRa depen-  S, 
dent, experiments were performed in the presence of mAb 
known to inhibit this interaction or a peptide containing the 
RGD sequence. The results are shown in Fig. 6. Pretreatment 
of M21-L/GP lib cells with mAb A2A9 inhibited their at- 
tachment to fibrinogen.  This inhibition was specific since 
neither the FnR MoAb BIIG2 nor the VnR MoAb LM609 
had an inhibitory effect. Attachment was also inhibited by 
RGDS but not by RGES at a final concentration of 50 ~M. 
When  plated  on  fibronectin,  MoAb  A2A9  had  no  effect 
whereas the MoAb BIIG2 inhibited M21-L/GP llb cell adhe- 
sion to a similar extent as RGD. Conversely, pretreatment of 
mock-transfected M21-L cells with BIIG2 inhibited their at- 
tachment to fibronectin, whereas mAb LM609 or A2A9 had 
no effect (results not shown). 
(b) Properties of GP lib-Ilia and the Vitronectin Recep- 
tor Constitutively Expressed in Nucleated Cells. To deter- 
mine whether the functional properties of the GP IIb-iRa in 
M21-L/GP llb cells corresponded to those of native GP llb- 
IRa constitutively expressed in nucleated cells, we compared 
those ofa subclone of the HEL cell line selected for high ex- 
pression of GP I1b-iRa and low expression of the VnR. As 
shown in Fig. 7, the subclone HEL-5J20 is characterized by 
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Figure 5. Adhesion of M21-W, M21-L, and M21-L/GP lib cells to 
extracellular  matrix  proteins.  3SS-metabolically labeled  M21-W 
cells (shaded bar), M21-L cells (white bar), or M21-L/GP lib cells 
(black bar) were allowed to attach to adhesive protein-coated mi- 
crotiter  wells  for  3  h  at  37°C  as  described  in  Materials  and 
Methods. After adhesion, unattached cells were washed away and 
the  remaining cells lysed with 2%  SDS. The radioactivity  from 
each well was counted in a ~ scintillation counter. Cell attachment 
was expressed as the number of cells (counts per minute) attached 
per well. Each bar represents the mean +  SD of three replicates. 
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Figure 6. Inhibition of M21-L/GP lib cell attachment to fibrinogen 
or fihronectin.  Metabolically  labeled  M21-L/GP  lib ceils  (5  x 
104) were  allowed to attach  to microtiter  wells coated  with  10 
#g/ml of fihrinogen or fibronectin. Before addition to the protein- 
coated wells, the ceRs were allowed to react with mAh IgG (10 t~g) 
or the synthetic peptides RGDS and RGES (final concentration 50 
#M). After 3 h at 37°C, unattached cells were washed off and the 
remaining radioactivity counted.  Cell attachment  is expressed as 
the number of cells (counts per minute) attached per well. Each bar 
represents the mean ±  SD of three replicates. 
The Journal of Cell Biology, Volume 113, 1991  456 NC 
anti-GPIIb-Illa 
HEL-AD1 
. 
anti-VnR 
~ 
J20 
Figure  7.  (Top) #3-integrin 
phenotype  of HEL-5J20  and 
HEL-AD1 ceils.  Washed un- 
fixed ceils were stained for in- 
direct immunofluorescence  and 
flow cytometry analysis using 
the GP IIb-I~a  mAb A2A9 or 
the vitronectin receptor mAb 
LM609.  Nonspecific fluores- 
cence (negative control, NC) 
was determined by incubating 
the cells with the second flu- 
orescein  isothiocyanate  anti- 
body alone.  (Abscissa, chan- 
nel  number  of  fluorescence 
intensity; ordinate, frequency 
of cells).  (Bottom) Quantita- 
tive  immunoprecipitation  of 
GP fib-Ilia, the VnR and the 
fibronectin receptor from ~I- 
surface labeled HEL-5J20 and 
HEL-AD1 cells. Detergent ex- 
tracts (600 t~g protein) of  HEL- 
5J20 cells and HEL-AD1 cells 
were  incubated  with  10  #g 
ofGP fib-IIIa  mAb A2A9 (A), 
VnR mAb LM609 (B), or the 
FnR mAb BIIG2, and the pre- 
cipitated  immune  complexes 
analyzed by SDS-PAGE  under 
reducing conditions. 
a  high expression of GP llb-IIIa and only background ex- 
pression of the VnR,  whereas the  subclone HEL-AD1  ex- 
presses similar amounts of both GP I/b-Ilia and the VnR. 
When the two HEL clones were studied for their adhesion 
properties, HEL-5J20 cells attached to fibrinogen but not to 
vitronectin  or  von Willebrand  factor,  whereas  HEL-AD1 
cells attached to all ligands (Fig. 8). Interestingly, similar to 
M21-L/GP fib cells,  adhesion to vitronectin or von Wille- 
brand factor could not be induced through activation of the 
protein kinase C pathway by PMA (data not shown). Together, 
these results provide evidence that in contrast to the VnR, GP 
IIb-IHa  expressed in nucleated cells mediates exclusively at- 
tachment to fibrinogen. 
(c) Resting Platelet GP lib-Ilia Mediates Platelet Adhe- 
sion to Immobilized Fibrinogen. GP llb-lTta-mediated plate- 
let adhesion to immobilized adhesive proteins is known to 
be activation dependent and adhesion assays are most com- 
monly performed with  thrombin-activated platelets  (Hav- 
erstick et al.,  1985;  Santoro and Cowan,  1986;  Cheresh et 
al.,  1989).  To determine whether GP Wo-l]Ia in its resting 
inactive form was able to mediate platelet attachment to im- 
mobilized fibrinogen, we compared the adhesive properties 
of platelets isolated in the presence of PGI2 with those of 
platelets activated with thrombin or PMA. As shown in Fig. 
9, resting PGI2-treated platelets attached to fibrinogen but not 
to vitronectin or yon Willebrand factor, whereas thrombin- 
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Figure 8. Adhesion of HEL-5J20 and HEL-AD1 cells to purified 
extracellular  matrix proteins. The adhesion assay was performed as 
described in the legend to Fig. 5. 
or PMA-activated platelets attached to fibrinogen, vitronec- 
tin, and von Wfllebrand factor. Also, attachment of PGI2- 
treated as well as PMA-treated platelets to fibrinogen could 
be inhibited by mAb A2A9 as well as the RGDS peptide (re- 
suits not shown). 
Discussion 
This study compares the adhesive activities of GI? l/b-IRa 
and the VnR on control, inactivated cells. Three approaches 
were used to characterize these properties. First, an expres- 
sion system was established so that the adhesive properties 
of GP l/b-RIa and the VnR could be compared in an other- 
wise identical cellular environment. As previously described 
(Cheresh and Spiro,  1987),  the VnR in M21 cells mediated 
cellular adhesion to fibrinogen, yon Willebrand factor and 
vitronectin. To measure the adhesive activity of GP l/b-IRa 
in these same cells we have expressed GP llb  in human 
M21-L cells which synthesize f33 but lack expression of the 
VnR. GP l/b-IRa in these cells, termed M21-L/GP lib, medi- 
ated cellular adhesion to fibrinogen but not to von grdle- 
brand factor or vitronectin. Second, variants of HEL cells 
were selected so that the adhesive activities of GP lib-IRa 
and the VnR could be compared in another cell type. It was 
found that while the VnR mediated cellular adhesion to fi- 
brinogen, yon Wtllebrand factor, and vitronectin, GP llb- 
IRa selectively mediated cellular adhesion to  fibrinogen. 
The third approach examines the ability of GP IIb-IRa to 
mediate the adhesion of unstimulated platelets to adhesive 
proteins. Although GP IIb-l/Ia on activated platelets binds 
the soluble form of the three adhesive proteins examined 
(reviewed in Plow et al., 1986), GP l/b-IRa on control plate- 
lets only mediated platelet adhesion to fibrinogen. We con- 
clude that the adhesive properties of GP Rb-iRa on unstimu- 
lated  platelets  and  nucleated cells  is  similar,  selectively 
mediating cellular adhesions to fibrinogen, and distinct from 
those of the VnR which mediate cellular adhesions in addi- 
tion to yon Willebrand factor and vitronectin. 
The present study was facilitated by the stable transfection 
of  full-length  cDNA coding GP ]To into M21-L cells. The GP 
IIb-iRa expressed on the surface of these cells after transfec- 
tion of GP IIb used the endogenous 133 (GPIRa) that these 
cells synthesized. Immunomagnetic bead selection rather 
than FACS was used for the initial isolation of transfectants 
expressing GP lib-Ilia. This was particularly useful since the 
beads provide a quick, inexpensive method that allowed easy 
isolation of the GP l/b-IRa positive cells and convenient vi- 
sualization of the morphologic changes that occurred when 
the selected cells were cultured on fibrinogen-coated plates. 
Although the beads remained bound to the cells for several 
days, they apparently did not interfere with cell attachment 
and  spreading,  cell  growth,  or  cell  division.  This  im- 
munomagnetic bead selection procedure might be useful for 
other  adhesive  protein  receptor  expression  systems  and 
represents an alternative method for the selection of stable 
transfectants. Immunological criteria were also used to show 
that the expressed protein in M21-L/GP IIb cells does indeed 
correspond to platelet GP l/b-IRa rather than a  revertant 
endogenous VnR.  Neither M21-L ceils nor M21-L/GP lTo 
cells bound the rnAb LM609, which recognizes a complex- 
dependent epitope of the VnR on M21-wild-type cells. In ad- 
dition, mAb  LM609 was unable to  immunoprecipitate a 
complex from metabolically labeled M21-L or M21-L/GP 
l/b cells, providing further evidence that these cells are de- 
void of an intracellular pool of the VnR. In contrast, mAb 
A2A9, which recognizes a complex-dependent determinant 
on GP l/b-IRa and does not cross-react with the VnR, exclu- 
sively reacted with the transfected M21-L/GP IIb cells from 
which it precipitated a complex corresponding to GP Hb- 
IRa. Finally, mAb SZ21,  which reacts with the individual 
/33 subunit common to GP IIb-IRa and the VnR,  precipi- 
tated the VnR only from M21-wild  type cells, the free/33 
subunit from M21-L cells and the GP IIb-IRa complex only 
from the transfected M21-L/GP lib cells. These results pro- 
vide evidence that our initial immunomagnetic bead cell en- 
richment method allowed successful identification and isola- 
tion of GP IIb-expressing M21-L ceils. 
Transfection of GP IIb into M21-L cells allowed complete 
posttranslational processing and surface expression of a GP 
l/b-IRa complex. This was documented by immunoprecipi- 
tation experiments performed in parallel on 125I-surface la- 
beled or [3~S]methionine labeled cells,  t2SI-labeled GP l/b- 
IRa from M21-L/GP l/b ceils comigrated with platelet GP 
l/b-iRa  under both nonreducing and  reducing conditions 
providing evidence that only the fully processed receptor 
reached the cell surface. The inability of mAb S1  (which 
reacts  with individual GP IIb  as  well as pro-GP  l/b)  to 
precipitate pro-GP  llb  from steady-state [35S]methionine- 
labeled M21-L/GP llb cells demonstrates the absence of an 
intracellular pool of unprocessed pro-GP l/b and suggests 
that pro-GP lib did associate with endogenous GP IRa to 
form the GP lib-IRa complex. This is in contrast with our 
results obtained after transient expression of the same pBJ1- 
GP lib construct in COS cells where only individual un- 
processed  pro-GP  Ub  could be  immunoprecipitated with 
mAb S1. In HEL cells, mAb SI precipitated pro-GP Wo as 
well as the processed GP IIb-IRa complex (Fig. 3).  Since 
COS  cells  express  a  dimeric  complex  immunologically 
related to the integrin/33 subunit, as identified by Western 
blot analysis and immunoprecipitation experiments using 
polyclonal rabbit IgG directed against GP lib-IRa (Kieffer, 
N., and D.  R.  Phillips, unpublished results), these results 
The Journal of Cell Biology, Volume 113,  1991  458 Figure  9.  Phase-contrast micro- 
graphs  of adhesion  assays per- 
formed with PGI2-treat,  d resting 
platelets  or  thrombin-activated 
plat,  lets.  Platelets were allowed 
to attach to microtiter wells  coated 
with fibrinogen (FIB), vitronec- 
tin (VN), von Willebrand factor 
(VWF), and BSA (BSA) as de- 
scribed  in Materials  and Meth- 
ods. After adhesion,  unattached 
platelets were washed off and the 
remaining cells were microphoto- 
graphed. Bar, 50 #m. 
suggest that human c,  n~ does not associate with monkey B3 
unlike murine od and avian B~, which do (Solowska et al., 
1989). 
The successful stable expression of GP llb-~Ia in M21-L 
cells  allowed us  to  compare the  functional properties of 
GPHb-ma and the VnR individually expressed in M21 cells, 
and to compare these properties with those of native GP lib- 
Ilia constitutively expressed in HEL ceils or platelets. For 
this purpose, subclones of the HEL cell line were selected 
that express either GP llb-llla (HEL-5J20) or GP IIb-IIIa 
and the vitronectin receptor (HEL-AD1). By using two dis- 
tinct cell systems as well as human platelets, we have been 
able to demonstrate that GP l/b-IIIa in its inactive, resting 
form is capable of mediating cell attachment to immobilized 
fibrinogen, but not to other RGD-containing adhesive pro- 
teins such as vitronectin or von Wtllebrand factor. Evidence 
to support this conclusion is derived from the following ex- 
periments. First, M21-L/GP lib cells as well as HEL cells 
expressing  GP  IIb-llla  attached  to  fibrinogen but  not  to 
vitronectin or  von Willebrand  factor,  whereas  HEL-AD1 
cells and M21 cells expressing the VnR did. Second, M21- 
L/GP llb cell-, HEL cell- or platelet interaction with im- 
mobilized fibrinogen could be specifically inhibited with a 
complex dependent anti-GP I/b-IIIa  mAb,  demonstrating 
that the observed cell attachment to fibrinogen was GP Iib- 
IIIa dependent. Third, in contrast to thrombin or PMA-acti- 
rated platelets,  which attach to RGD-containing adhesive 
proteins such as fibrinogen, vitronectin, or von Willebrand 
factor, PGI2-treated resting platelets attached exclusively to 
immobilized fibrinogen. Finally, that PMA did not induce 
M21-L/GP llb or HEL cell attachment to vitronectin or yon 
Willebrand factor suggests that in nucleated ceils, GP Hb- 
IIIa is blocked in a functional state similar to that of resting 
platelets. 
Since resting platelets and nucleated cells expressing GP 
l/b-lIIa attach to immobilized fibrinogen but are unable to 
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Thiagarajan e1 al., 1987; Kieffer, N., and D. R. Phillips, un- 
published results), the molecular mechanism underlying sol- 
uble versus immobilized fibrinogen/GP IIb-iRa interaction 
must be distinct. Cheresh et al. (1989) have recently shown 
that vitronectin  receptor-dependent  endothelial  cell adhe- 
sion to immobilized fibrinogen is exclusively mediated through 
the RGD-containing  site near  the COOH terminus  of the 
fibrinogen Aot chain,  whereas GP Ilb-iRa-mediated adhe- 
sion of activated platelets to fibrinogen involves either RGD 
sequences as well as the COOH terminus portion of the 3' 
chain. Our results suggest that in contrast to activated plate- 
lets, GP 11b-HIa mediated attachment of resting platelets to 
immobilized fibrinogen might be mediated through the do- 
decapeptide sequence of the fibrinogen 3' chain, since this se- 
quence is unique to fibrinogen among the adhesive proteins, 
whereas  GP IIb-lIIa-mediated  adhesion  to other adhesive 
proteins such as vitronectin or yon Willebrand factor is de- 
pendent on the RGD recognition sites and requires the acti- 
vated form of GP 11b-lTla. Shiba et al. (Shiba, E., J. Lindon, 
M. Kloczawiak, J. Hawiger, G. Matsueda,  B. Kudryk, and 
E.  W. Salzman.  1988.  Circulation. 78:11662.) have indeed 
shown that antibodies generated against the peptide 385-411 
of the fibrinogen 3' chain are effective in blocking the in- 
teraction of human platelets with fibrinogen adsorbed to a 
synthetic  polymer  surface.  Alternatively,  conformational 
changes  of the RGD sequence in  immobilized  fibrinogen 
might increase its affinity for resting  GPllb-11Ia.  Together 
with the data of Lindon et al. (1986), it is therefore tempting 
to speculate that changes in the conformation of immobilized 
fibrinogen lead to the exposure of recognition sites (3' chain 
dodecapeptide and/or a high-affinity RGD site) which are not 
accessible on soluble fibrinogen.  Finally,  due to the high 
density of immobilized fibrinogen molecules, several uniden- 
tiffed binding sites with modest affinities might cooperate to 
function as multivalent ligands for resting GP fib-Ilia and 
allow a sufficiently high degree of adhesive specificity and 
affinity. 
The expression of immunoreactive and functional GP fib- 
Ilia on M21-L/GP fib cells provides evidence that a trans- 
fected exogenous ot  ab subunit can form heterodimers  with 
an existing endogenous VnR/~3 subunit and rescue a  fully 
complexed c~nb/33 receptor on the cell surface. This result is 
of particular interest with respect to patients with the genetic 
integrin  deficiency  Glanzmann's  thrombasthenia,  an  au- 
tosomal recessive hemorrhagic disorder caused by a quan- 
titative or qualitative defect of GP fib-iRa to bind fibrinogen 
(for a review see George et al., 1990). Although the molecu- 
lar basis for GP fib-iRa deficiency in thrombasthenic  pa- 
tients is still unclear, the biosynthetic pathway of GP fib-IRa 
(Bray et al.,  1986, Duperray et al.,  1987,  1989; Rosa et al., 
1989) suggests that a defect in only one of the glycoprotein 
subunits would prevent the formation of the complex and its 
insertion  into  the  membrane.  Indeed,  in  several  throm- 
basthenic patients characterized  by a  complete absence of 
surface expression of  the GP fib-IRa complex, trace amounts 
of GP fib and GP HIa or GP IRa alone could be detected by 
immunoblotting (Nurden et al.,  1985; Coller et al.,  1987). 
Also,  normal  expression of the VnR (otv/33) in endothelial 
cells of a patient lacking platelet GP fib-IHa suggest that this 
type of thrombasthenia is caused by defective synthesis of GP 
fib (Giltay et al.,  1987). M21-L cells, which have an intra- 
cellular pool of free GP Ilia, mimic the GP lTo-defective type 
of Glanzmann's  thrombasthenia,  and thus constitute an ex- 
ceUent human  experimental  cell  model  for integrin  gene 
therapy in this disease. 
Finally, our data provide a molecular model for the under- 
standing  of some physiological aspects of hemostasis and 
thrombosis.  The interaction of resting platelet GP nb-ltla 
with immobilized fibrinogen constitutes a possible mecha- 
nism by which unactivated platelets are recruited into grow- 
ing thrombi. Since this mechanism might also play a key role 
in platelet adhesion to artificial surfaces used for prosthetic 
arterial grafts or dialysis membranes (Lindon et al.,  1986; 
McManama et al.,  1986),  the design of artificial  surfaces 
resistant to fibrinogen adsorption appears to be a,prerequi- 
site for the development of nonthrombogenic materials. 
We thank Dr. C. Damsky (Department of Stomatology, UCSF) for the gift 
of the VnR mAb BIIG2. We also wish to thank Bill Hyun (Laboratory for 
Cell Analysis, UCSF) for his expert technical assistance with FACS analy- 
sis and cell sorting. 
This work was supported in part by National Institutes of Health grant 
HL-28947. 
Received for publication 18 September 1990 and in revised form 28 De- 
cember 1990. 
R~f~.rGflce$ 
Bennett, J. S., J. A. Hoxie, S. F. Leitman, G. Vilaire, and D. B. Cines. 1983. 
Inhibition of fibrinogen binding to stimulated human  platelets by a monoclo- 
nal antibody. Proc. Natl. Acad.  Sci. USA. 80:2417-2421. 
Bodary, S. C., M. A. Napier, and J. W. McLean. 1989. Expression of recom- 
binant platelet glycoprotein llb-HIa results in a functional  fibrinogen,binding 
complex. J. Biol. Chem. 264:18859-18862. 
Bray, P. F., J.  P. Rosa, V. R. Lingappa. Y. W. Kahn, R. P. McEver, and 
M. A. Shuman. 1986. Biogenesis of the platelet receptor for fibrinogen:  evi- 
dence for separate precursors for glycoproteins fib and Ilia.  Proc. Natl. 
Acad.  Sci. USA. 83:1480-1484. 
Cheresh, D. A., and R. C. Spiro. 1987. Biosynthetic and functional properties 
of an Arg-Gly-Asp-directed receptor involved in human melanoma cell at- 
tachment to  vitronectin,  fibrinogen and yon Willebrand factor.  J.  Biol. 
Chem. 262:17703-17711. 
Cheresh, D. A., S. A. Befliner, V. Vincente, and Z. Ruggeri. 1989. Recogni- 
tion of distinct adhesive sites on fibrinogen by related integrins on platelets 
and endothelial cells. Cell. 58:945-953. 
Coller, B. S. 1980. Interaction of normal, thrombasthenic, and Bernard-Soulier 
platelets  with immobilized flbrinogen: defective platelet-fibrinogen  interac- 
tion in thrombastbenia. Blood.  55:169-178. 
Coller, B. S., U. Seligsohn, and P. Little. 1987. Type I Glanzmann's throm- 
basthenia patients from the Iraqi-Jewish and Arab population in Israel can 
be  differentiated  by  platelet  glycoprotein  GPIIIa  immunoblot analysis. 
B/ood.  69:1696-1703. 
Conforti, G., A. Zanetti, I. Pasquali-Ronchetti, Jr., D. Quaglino, P. Neyroz, 
and E. Dejana.  1990. Modulation of vitronectin receptor binding by mem- 
brane lipid composition. J.  Biol. Chem. 265:4011--4019. 
D'Souza, S. E., M. H. Ginsberg, T. A. Burke, S. C.-T. Lain, and E. F. Plow. 
1988.  Localization of an Arg-Gly-Asp recognition site within an integrin 
receptor. Science (Wash. DC). 242:91-93. 
D'Souza, S. E.,  M. H. Ginsberg, T. A. Burke, and E.  D. Plow.  1990.  The 
ligand binding site of the platelet integrin receptor GPfib-IIla is proximal to 
the  second  calcium binding  domain of its  ct  subanit.  J.  Biol. Chem. 
265: 3440- 3446. 
Duperray, A., R. Berthier,  E. Chagnon, J. L  Ryckewaert, M. Ginsberg, E. 
Plow,  and G.  Marguerie.  1987.  Biosynthesis and processing of platelet 
GPHb-IlIa  in human megakaryocytes. J.  Cell Biol.  104:1665-1673. 
Duperray, A., A. Troesch, R. Berthier, E. Chagnon, P. Frachet, G. Uzan, and 
G. Marguerie. 1989. Biosynthesis  and assembly  of platelet GPllb-llla in hu- 
man  megakaryocytes: Evidence that assembly  between pro-GPBb and GPllla 
is a prerequisite for expression of the complex on the cell surface. Blood. 
74:1603-1611. 
Doolittle,  R. F., K. W. K. Watt, B. A. Cottreil, D. D. Strong, and M. Riley. 
1979. The amino acid sequence of the a-chain of human fibrinogen.  Nature 
(Load.).  280:464-467. 
Elices,  M. J., and M. E. Hemler. 1989. The integrin VLA-2 can be a laminin 
as well as a collagen receptor.  Proc. Natl. Acad. Sci. USA. 86:9906-9910. 
Engvall, E., E. Ruoslahti, and E. J. Miller.  1978. Affinity of fibronectin to colla- 
gens of different  genetic types and to fibrinogen.  J.  Exp. Med. 147:1584- 
The Journal of Cell Biology, Volume 113,  1991  460 1595. 
Feigner, P. L., T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, 
J. P. Northrop, G. M. Ringold, and M. Danielson. 1987. Lipofectin: a high 
efficient, lipid-mediated DNA-transfection  procedure. Proc. Natl. Acad. Sci. 
USA. 84:7413-7417. 
Fitzgerald, L. A., and D. R. Phillips. 1985. Calcium regulation of the platelet 
membrane glycoprotein lib-Ilia complex. J. Biol. Chem. 260:11366-11374. 
Fitzgerald, L. A., M. Poncz, B. Steiner, S. C. Rail, J. S. Bennett, and D. R. 
Phillips. 1987. Comparison of cDNA-derived protein sequences of the hu- 
man fibronectin and vitronectin receptor t~ subuhits  and platelet glycoprotein 
Lro. Biochemistry.  26:8158-8165. 
George, J. N., J. P. Caen, and A. T. Nurden. 1990. Glanzmann's  thrombasthe- 
nia:  the spectrum of clinical  disease. Blood.  75:1383-1395. 
Giltay, J. C., O. C. Loeksma, C. Breederveld, and J. A. van Mourik. 1987. 
Normal synthesis and expression of endothelial IIb/IIIa  in Glanzmann's 
thrombasthenia. Blood.  69:809-812. 
Gluzman, Y.  1981.  SV40-transformed simian cells support the replication  of 
early SV40 mutants. Cell. 23:175-182. 
Haverstick, D. M., J. F. Cowan, K. M. Yamada, and S. A. Santoro.  1985. 
Inhibition of platelet adhesion to fibronectin,  fibrinogen and yon Willebrand 
factor substrates by a synthetic tetrapeptide derived from the cell-binding do- 
main of fibronectin.  Blood.  66:946-952. 
Hawiger, J., S. Timmons, M. Kloczewiak,  D. D. Strong, and R. F. Doolitlle. 
1982.3' and c~ chains of human fibrinogen possess sites reactive with human 
receptor. Proc. Natl. Acad.  Sci. USA. 79:2068-2071. 
Hemler, M. E., C. Crouse, Y. Takada, and A. Sonnenberg. 1988.  Multiple 
very late antigen (VLA) heterodimers on platelets:  evidence for distinct 
VLA-2, VLA-5 (fibronectin  receptor)  and VLA-6 structures. J. Biol. Chem. 
263:7660-7665. 
Hynes, R. O.  1987.  Integrins: a  family of cell surface receptors.  Cell. 48: 
549-554. 
Kazal, L. A., S. Amsel, O. P. Miller, and L. M. Tocantins. 1963. The prepara- 
tion and some properties of fibrinogen precipitated from human plasma gly- 
cine. Proc.  Soc. Exp. Biol. Med.  131:989-994. 
Kieffer, N., N. Debili, A. Wicki, M. Titeux, A. Henri, M. Zohair, J. Breton- 
Gorius, W. Vainchenker, and K. Clemetson. 1986.  Expression of platelet 
glycoprotein Ibc~ in HEL cells. J. Biol. Chem. 261:15854-15862. 
Kirchhofer, D., L. R. Languino, E. Ruoslahti, and M. D. Pierschbacher. 1989. 
Alpha 2 beta 1 integrins from different  cell types show different binding 
specificities.  Z  Biol. Chem. 265:615-618. 
Kloczewiak, M., S. Timmons, T. J.  Lukas, and L  Hawiger.  1984.  Platelet 
receptor recognition sites on human fibrinogen. Synthesis and structure- 
function relationship of peptides corresponding to the carboxy terminal seg- 
ment of the "r chain. Biochemistry.  23:1764-1774. 
Kunicki, T. J., D. J. Nugent, S. J. Staats,  R. P. Orchekowski, E. A. Wayner, 
and W. G. Carter. 1988. The human fibroblast  class II extracellular matrix 
receptor mediates platelet adhesion to collagen and is identical to the platelet 
GPIa-IIa complex. J.  Biol. Chem. 263:4516--4519. 
Kunkel,  T.  A.  1985.  Rapid and efficient  site-specific  mutagenesis without 
phenotypic selection. Proc. Natl.  Acad. Sci. USA. 82:488--492. 
I.aemmli, U. K. 1970. Cleavage of structural proteins during the assembly of 
the head of bacteriophage T4. Nature  (Lond.). 227:680-685. 
Lam, S. C. T., E. F. Plow, M. A. Smith, A. Andrieux, J. J. Ryckwaert, G. 
Marguerie,  and  M.  H.  Ginsberg.  1987.  Evidence  that  arginyl-glycyl- 
aspartnte peptides and fibrinogen 3' chain peptides share a common binding 
site on platelets.  J. Biol.  Chem. 262:947-950. 
Lain, S. C. T., E. F. Plow, S. E. D'Souza, D. A. Cheresh, A. L. Frelinger 
11I, and M. H. Ginsberg. 1989.  Isolation and characterization of a platelet 
membrane protein related to the vitronectin receptor. J.  Biol. Chem. 264: 
3742-3749. 
Lindon, J. N., G. McManama, L. Kuslmer, E. W. Merrill, and E. N. Salzrnan. 
1986. Does the conformation of adsorbed fibrinogen dictate platelet interac- 
tions with artificial  surfaces? Blood.  68:355-362. 
Marguerie, G. A., E. F. Plow, and T. S. Edginton. 1979. Human platelets pos- 
sess an inducible and saturable receptor specific  for fibrinogen. J.  Biol. 
Chem. 254:5357-5363. 
Martin, P., and T. Papayannopoulou. 1982. HEL cells: a new erythroleukemia 
cell line with spontaneous and induced globin expression. Science  (Wash. 
DC). 216:1233-1234. 
McManama, G., J. N. Lindon, M. Kloczewiak, M. A. Smith, J. A. Ware, J. 
Hawiger, E. W. Merill, and E. W. Salzman. 1986.  Platelet aggregation by 
fibrinogen polymers crosslinked across the E domain. Blood. 68:363-371. 
Niewiarowski, S., E. Regoeczi, G. J. Stewart,  A. F. Senyi, and J. F. Mustard. 
1972.  Platelet  interaction  with  polymerizing  fibrin.  J.  Clin. Invest. 
51:685-700. 
Nurden, A.  T.,  D.  Didry,  N.  Kieffer,  and R.  P.  McEver.  1985.  Residual 
amounts of glycoproteins GPIIb and Gpllla may be present in the platelets 
of most patients with Glanzmann's thrombasthenia. Blood.  65:1021-1024. 
O'Toole, T. E., J. C. Loftus, E. F. Plow, A. A. Glass, J. R. Harper, andM. H. 
Ginsberg. 1989. Efficient surface expression of platelet  GPIIb-IIIa  requires 
both subunits. Blood.  74:14-18. 
Phillips, D. R., I.  F. Charo, L. V. Parise, and L. A. Fitzgerald.  1988.  The 
platelet membrane glycoprotein Ilb-Illa complex. Blood.  71:831-843. 
Piotrowicz,  R. S., R. P. Orchekowski, D. J. Nugent, K. Y. Yamada, and T. J. 
Kunicki. 1988.  Glycoprotein Ic-IIa functions as an activation-independent 
fibronectin receptor on human platelets. J.  Cell Biol.  106:1359-1364. 
Plow, E.  F., M.  H. Ginsberg, and G. A. Marguerie.  1986.  Expression and 
function of adhesive proteins on the platelet  surface. In  Biochemistry of 
Platelets,  D. R. Phillips and M. A. Shuman editors. Academic Press, Or- 
lando, FL. 225-256. 
Poncz, M., R. Eisman, R. Heidenreich, S. Silver, G. Vilaire, S. Surrey, E. 
Schwartz, and J. S. Bennett. 1987. Structure of the platelet membrane glyco- 
protein IFo: homology to the a  subunits of the vitronectin and fibronectin 
receptors. J.  Biol. Chem. 262:8476-8482. 
Rosa, J. P., and R. P. McEver. 1989. Processing and assembly of the integrin, 
glycoprotein IIb-IIla,  in HEL cells. J.  Biol.  Chem. 264:12596-12603. 
Ruoslahii, E., and M. D. Pierschbacher. 1987. New perspectives in cell adhe- 
sion: RGD and integrins. Science  (Wash. DC).  238:491-497. 
Santoro, S. A., and J. F. Cowan. 1986. Thrombin enhances adhesion of plate- 
lets to von Willebrand factor substrates. Thromb. Res. 43:57-72. 
Smith, J. W., and D. A. Cheresh. 1988. The Arg-Gly-Asp binding domain of 
the vitronectin receptor. J. BioL  Chem. 263:18726-18731. 
Solowska, I., J.-L. Guan, E. E. Mercantonio, J. E. Trevithick, C. A. Buck, 
and R. O. Hynes.  1989.  Expression of normal and mutant avian integrin 
subunits in rodent cells. J.  Cell Biol. 109:853-861. 
Steiner,  B.,  D. Cousot, A. Trzeciak,  D.  Gillessen, and P.  Hadvery.  1989. 
Ca2+-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a sin- 
gle site on purified  platelet  glycoprotein llb-llIa complex. J.  Biol.  Chem. 
264:13102-13108. 
Takebe, Y., M.  Seiki,  J.  I.  Fujisawa, P.  Hoy, K. Yokota, K. I.  Aral, M. 
Yoshiba, and N. Arai. 1988. SRt~ promoter: an efficient and versatile mam- 
malian cDNA expression system composed of the simian virus 40 early pro- 
motet and the R-U5 segment  of human T-cell leukemia virus type 1 long ter- 
minal repeat.  Mol. Cell. Biol. 8:466--472. 
Thiagarajan, P., S. S. Shapiro, L. Sweterlitsch, and S. McCord. 1987. A hu- 
man erythroleukemia cell line synthesizes a functionally active glycoprotein 
IIb-IHa  complex capable of binding fibrinogen. Biochem.  Biophys. Acta. 
924:127-134. 
Werb, Z., P. M. Tremble, O. Behrendtsen, E. Crowley, and C. H. Damsky. 
1989.  Signal  transduction through the  fibronectin  receptor  induces col- 
lagenase and stromelysin gene expression. J.  Cell Biol. 109:877-889. 
Yatohga, T., I. Masako, K. Heiachiro, and M. Hayashi. 1988. Novel purifica- 
tion of vitronectin from human plasma by heparin affinity chromatography. 
Cell Struct. Funct. 13:281-292. 
Kieffer et al. Properties of GP lib-Ilia  Expressed in Human Melanoma  Cells  461 